Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: Oligomeric tau-targeted immunotherapy in Tg4510 mice

Fig. 3

Tg4510 mice injected systemically with TOMA present elevated levels of oligomers in both CSF and plasma. Quantitative analysis of oligomeric tau in CSF (a) and plasma (b) of nontransgenic mice (nTg, white bars), Tet-only mice (Tet, grey bars), and Tg4510 mice treated with IgG1 (Tg4510 IgG1, black bars) or TOMA (Tg4510 TOMA, striped bars) for 5 months. Analyses were performed using both direct and sandwich ELISA. T22 was used for tau oligomers. Two-way ANOVA showed a significant increase in levels of oligomers in both CSF of Tg4510 mice treated with TOMA compared to Tg4510 mice treated with IgG1 and nontransgenic and Tet-only control mice. Data presented as mean ± SEM, ***p < 0.001. CSF cerebrospinal fluid, TOMA tau oligomer monoclonal antibody, OD optical density

Back to article page